ArticleCancers2025

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study.

Safa Can Efil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.